Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-05-17
2005-05-17
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388730, C530S388800, C530S388850, C530S391700
Reexamination Certificate
active
06894149
ABSTRACT:
This invention provides anti-HLA-DR antibodies and the methods of use thereof for the treatment of leukemia or lymphomas, or solid tumors such as ovarian cancer or melanoma.
REFERENCES:
patent: 5004692 (1991-04-01), Tso et al.
patent: 5301101 (1994-04-01), MacArthur et al.
patent: 5552530 (1996-09-01), Johnson et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 6086900 (2000-07-01), Draper
patent: 6129914 (2000-10-01), Weiner et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6416958 (2002-07-01), Vidovic et al.
patent: 6420140 (2002-07-01), Hori et al.
patent: WO 9117271 (1991-06-01), None
patent: WO 9110741 (1991-07-01), None
patent: WO 9201047 (1992-10-01), None
patent: WO 9312227 (1993-06-01), None
patent: WO 9617874 (1996-06-01), None
patent: PCTUS02/32491 (2003-12-01), None
Baldwin, et al.,Monoclonal Antibodies for Cancer Detection and Therapy, Academic Press (1985).
Bird Robert E., et al., Single-Chain Antigen-Binding Proteins,Science, 242:423-6 (1988).
Brown, Eric J., “In Vitro Assays of Phagocytic Function of Human Peripheral Blood Leukocytes: Receptor Modulation and Signal Transduction”,Methods in Cell Biol. 45:147 (1994).
Byers, Vera S., et al., “Rationale for Clinical Use of Immunotoxins in Cancer and Autoimmune Disease”,Seminars Cell Biol. 2:59-70 (1991).
Demur, C., et al., “Effects of an Anti HLA-DR immunotoxin on Leukemic Cells and Hemopoietic Progenitors”,Leuk. Res. 13(12):1047-54 (1989).
Fanger, Michael W., et al., “Bispecific Antibodies and Targeted Cellular Cytotoxicity”,Immunol. Today12:51-4 (1991).
Green, Jennifer M., et al., “Role of Cholesterol in Formation and Function of a Signaling Complex Involving Alphavβ3, Integrin-associated Protein (CD47), and Heterotrimeric G Proteins”,J. Cell Biol. 146:673-82 (1999).
Greinix, H. T., et al., “Specific Growth Inhibition of Primative Hematopoietic Progenitor Cells Mediated Through Monoclonal Antibody Binding to MHC Class II Molecules”,Blood80(8):1950-1956 (1992).
Hajeer, A. H., et al., “Antibodies to Major Histocompatibility Complex Class II Inhibit Proliferation but Increase Production of Soluble CD23 in Lymphoblastoid B-Cell Lines”,Immunol. 80(4):593-7 (1993).
Higaki, Y., et al., “Mechanisms Involved in the Inhibition of Growth of a Human B Lymphoma Cell Line, B104, by Anti-MHC Class II Antibodies”,Immunol. Cell Biol. 72(3):205-14 (1994).
Hill, Mark, et al., “Exploration of Requirements for Peptide Binding to HLA DRB1*0101 and DRB1*0401”,J. Immunol. 152, 2890-2898 (1994).
Hood et al., “Immunology”,Benjamin, N.Y., 2nd ed. (1984).
Hu, Eddie, et al., “A Phase 1a Clinical Trial of LYM-1 Monoclonal Antibody Serotherapy in Patients with Refractory B Cell Malignancies”,Hematol. Oncol. 7(2):155-66 (1989).
Hunkapiller, Tim, et al., “The Growing Immunoglobulin Gene Superfamily”,Nature, 323:15-16 (1986).
Houston, et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced inEscherichia Coli”, Proc. Natl. Acad. Sci. U.S.A., 85:5879-83 (1988).
Kosteiny, et al., “Humanization and Characterization of the Anti-HLA-DR Antibody 1D10”,Int. J. Cancer93:(4):556-65 (2001).
Lampson, et al., “Two Populations of la-Like Molecules on a Human B Cell Line”,Journal of Immunology, 125(1): 293-99 (1980).
Landolfi, Nicholas F., et al., “Activated T-Lymphocytes Express Class I Molecules Which are Hyposialylated Compared to Other Lymphocyte Populations”,Molecular Immunol. 23, 297-309 (1986).
Lanzavecchia A, et al., “The Use of Hybrid Hybridomas to Target Human Cytotoxic T-Lymphocytes”,Eur. J. Immunol., 17:105 (1987).
Mendelsohn, “Epidermal Growth Factor Receptor Inhibition by a Monoclonal Antibody as Anticancer Therapy”,Foundations of Clinical Cancer Research: Perspective for the 21stCentury, 3(12) part 2 of 2 : 2703-07 (1997).
Miller, Chad G., “Adsorptive Biphasic Column Technology for Protein Sequence Analysis and Protein Chemical Modification”,Methods: A Companion to Methods in Enzymology6, 315-33 (1994).
Morgan, A., et al., “The N-Terminal End of the CH2 Domain of Chimeric Human IgG1 Anti-HLA-DR is Necessay for C1q, FcyR1 and FcyR111 Binding”,Immunol. 86(2):319-24 (1995).
Nagy, Zoltan A., et al., “Fully human, HLA-DR-Specific Monoclonal Antibodies Efficient Induce Programmed Death of Malignant Lymphoid Cells”,Nat Med. 8(8):801-7 (2002).
Newell, M. Karen, et al., “Ligation of Major Histocompatibility Complex Class II Molecules Mediates Apoptotic Cell Death in Restin gB Lymphocytes”,Proc. Natl. Acad. Sci. 90:10459-63 (1993).
O'Boyle, Kevin, et al., “Potentiation of Antiproliferative Effects of Monoclonal Antibody Lym1 and Immunoconjugate Lym-1-Gelonin on Human Burkitt's Lymphoma Cells with Gamma-Interferon and Tumor Necrosis Factor”,J. Immunother. Emphasis Tumor Immunol. 18(4):221-30 (1995).
Olsnes, Sjur, et al., “Chimeric Toxins,” Pharmac. Ther., 15:355-81 (1982).
Ottonello, Luciano, et al., “Monoclonal Lym-1 Antibody-Dependent Lysis of B-Lymphoblastoid Tumor Targets by Human Complement and Cytokine-Exposed Mononuclear and Neutrophilic Polymorphonuclear Leukocytes”,Blood87(12):5171-8 (1996).
Pistillo, M. P.; et al., “Analysis of HLA Specificity of Human Monoclonal Antibodies by Cytofluorimetry and Cell ELISA”,Eur. J. Immunogenet18(5-6):345-53 (1991).
Remiington's Pharmaceutical Science(15th Ed., Mack Publishing Company, Easton, Pa., 1980).
Rose, L. M., et al., “Critical Lym-1 Binding Residues on Polymorphic Hla-DR Molecules”,Mol. Immunol. 36(11-12);789-97 (1999).
Simons, K., et al., “Lipid Rafts and Signal Transduction”,Nature Reviews / Molecular Cell Biology., 1:31-9 (2000).
Truman, Jean-Philip, et al., “Lymphocute Programmed Cell Death is Mediated Via HLA Class II DR”,Int. Immunol. 6(6):887-96 (1994).
Vidovic, Damir, et al., “Down-Regulation of Class II Major Histocompatibility Complex Molecules on Antigen-Presenting Cells by Antibody Fragments”,Eur. J. Immunol. 25(12):3349-55 (1995).
Vidovic, D., et al., “Selective Apoptosis of Neoplastic Cells by the HLA-DR Specific Monoclonal Antibody”,Cancer Letters128:127-135 (1998).
Viken, Helge D., et al., “Serologic Subtyping of HLA-DR8 by Means of the Cytoxic Human Monoclonal Antibody 5643”,Hum. Immunol. 43(3):200-6 (1995).
Würflein, Dieter, et al., “Evaluating Antibodies for Their Capacity to Induce Cell-mediated Lysis of Malignant B Cells”,Cancer Research58:3051-58(1998).
Dadmarz, et al., “Tumor-Infiltrating Lymphocytes from Human Ovarian Cancer Patients recognize Autologous tumor in an MHC Class II-Restricted Fashion,”Cancer J. Sci. Am. 2(5):263 (1996) (abstract only).
Friedrich, et al., “Testing of acute myeloid leukemia of humans using monoclonal antibodies BL-DR, BL-M/G, BL-T2 and BL-IG-L/1,”Acta Histochem. Suppl. 35:189-92 (1988) (abstract only).
Norose, et al., “Melanoma specific TH1 cytotoxic T Lymphocyte lines in Vogt-Koyanagi-Harada disease,”Br. J. Opthalmol. 80(11): 1002-8 (1996) (abstract only).
Swanson, et al., “HLA-DR (la-like) reactivity in tumors of bone and soft tissue: an immunohistochemical comparison of monoclonal antibodies LN3 and LK8D3 in routinely processed specimens,”Mod. Pathol. 3(2): 113-9 (1990) (abstract only).
Van Vreesswijk, et al., “Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma,”J. Invest. Dermatol. 90(5): 755-60 (1998) (abstract only).
Green Jennifer McPhate
Tso J. Yun
Blanchard David J.
Helms Larry R.
Howrey Simon Arnold & White , LLP
Protein Design Labs, Inc.
Whiting Adam K.
LandOfFree
Anti-HLA-DA antibodies and the methods of using thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-HLA-DA antibodies and the methods of using thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-HLA-DA antibodies and the methods of using thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455507